Follow us on Twitter
twitter icon@FreshPatents


Cholesterol patents

      

This page is updated frequently with new Cholesterol-related patent applications.




 Mrna therapy for phenylketonuria patent thumbnailMrna therapy for phenylketonuria
The present invention provides, among other things, methods of treating phenylketonuria (pku), including administering to a subject in need of treatment a composition comprising an mrna encoding phenylalanine hydroxylase (pah) at an effective dose and an administration interval such that at least one symptom or feature of pku is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.


 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses patent thumbnailCycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


 Composition comprising scirpusin a and scirpusin b and anti-obesity potential thereof patent thumbnailComposition comprising scirpusin a and scirpusin b and anti-obesity potential thereof
Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.. .

 Extracts of cyclanthera pedata and formulations and uses thereof patent thumbnailExtracts of cyclanthera pedata and formulations and uses thereof
The invention provides a method for extracting active therapeutic components from plant materials of the cyclanthera pedata plant which comprises immersing said plant material containing active components and selected from the group consisting of fruits, flowers, leaves, stems, twigs, bark, wood, buds, seeds, roots, and pods in a solvent for a period of time of about 30 minutes to about 10 hours to achieve transfer of active components from the plant material to the solvent, separating the solvent containing active components from the plant material, and evaporating or distilling the solvent to produce a concentrated fraction containing active components. The invention further includes compositions and therapeutic formulations of such extracts to treat hypercholesterolemia and other high lipid related diseases..

 Pharmaceutical composition based on a hepatoprotector and prebiotic, and  administrating patent thumbnailPharmaceutical composition based on a hepatoprotector and prebiotic, and administrating
The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

 Methods of determining efficacy of therapy for niemann-pick c disease and related disorders patent thumbnailMethods of determining efficacy of therapy for niemann-pick c disease and related disorders
A method for identifying and screening subjects for cholesterol storage or trafficking diseases using an oxysterol as a biomarker. More particularly, subjects are screened and can be identified as having niemann-pick c disease, the method comprising the steps quantifying the concentration of an oxysterol in a biological sample taken from the subject and comparing the concentration of the oxysterol of the subject to a reference value of the oxysterol derived from a non-affected subject population.
The United States Of America, National Institutes Of Health, As Represented By The Sec. Dept Hhs


 Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device patent thumbnailPcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments provide swallowable devices, preparations and methods for delivering therapeutic agents (tas) within the gi tract such as antibodies (ap-antibodies) or other proteins which neutralize pcsk9 molecules. Many embodiments provide a swallowable device e.g., a capsule for delivering tas into the intestinal wall (iw).
Rani Therapeutics, Llc


 Lactococcus lactis strains patent thumbnailLactococcus lactis strains
New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentación Y Desarrollo, A.c. (ciad)


 Lactococcus lactis strains patent thumbnailLactococcus lactis strains
New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentacion Y Desarrollo, A.c. (ciad)


 Serum cholesterol lowering edible product patent thumbnailSerum cholesterol lowering edible product
The present invention relates to a serum ldl cholesterol lowering edible product containing plant sterol ester and/or plant stanol ester, and especially to a dietary supplement product.. .
Raisio Nutrition Ltd


Proliposomal testosterone formulations

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc

Cell culture media

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (atra) and vitamin c; zinc, magnesium, and copper; an agent that increases intracellular camp; epidermal growth factor (egf); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin d, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.. .
The University Of Florida Research Foundation, Inc

Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction

The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in inhibiting cholesterol-induced cytochrome c peroxidase activity, promoting reduction of cytochrome c, and inhibition of cardiolipin peroxidation to treat, prevent or ameliorate cholesterol-induced mitochondrial dysfunction..
Cornell University

Method of lowering cholesterol

The present invention relates to the diagnosis, risk assessment, prevention, and treatment of senile dementia of the alzheimer's type (sdat). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum.
Phenomenome Discoveries Inc.

Fat-based food products

The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation..
Ip Science Limited

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Derivatives of ergostatrien-3-beta-ol from antrodia camphorata and antiglycemic, antihyperlipidemic and decreasing hepatic fat use thereof

The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3β-ol and its derivatives, as well as a method for decreasing blood glucose and hba1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood hdl-c levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (glut4) and phospho-akt in skeletal muscle tissue, and phospho-ampk in both skeletal muscle and liver tissue using ergostatrien-3β-ol and its derivatives.. .

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Methods targeting mir-128 for regulating cholesterol/lipid metabolism

Methods for targeting microrna 128 (mir-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.. .
The General Hospital Corporation

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc

Liposome composition and producing same

Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase..
Fujifilm Corporation

Use of cilastatin to reduce the nephrotoxicity of different compounds

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

Novel 7-dehydrocholesterol derivatives and methods using same

The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7dhc) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human.
Women & Infants Hospital Of Rhode Island

Compositions for the treatment of cataracts

In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-oso3h (5-cholesten-3β,25-sulfate), 5-cholesten-3β-oso3h,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.. .
Catacore, Inc.

Use of delta tocopherol for the treatment of lysosomal storage disorders

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders.
The United States Of America, As Represented By Secretary, Dept. Of Health & Human Services

Control device for a motor vehicle and control method

The present invention relates to a new process for the synthesis of colesevelam, which is used in therapy in cases of hypercholesterolemia due to low density lipoproteins. Said process comprises the reaction, in a basic environment, of polyallylamine with: i) at least one alkylating agent of formula x—(ch2)9—ch3 and at least one alkylating agent of formula y—(ch2)6—n+ (ch3)3z−, wherein x and y are each independently a leaving group, and z is a halogen; and ii) at least one crosslinking agent.
Dav

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel forms of [r, (r*,r*)]-2-(4-fluorophenyl)-β,δdihydroxy-5-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, forms xxv, form xxvii, form xxviii, form xxxix, and forms xxx, characterized by their x-ray powder diffractor, solid state nmr, and/or raman spectroscopy are describes as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer) disease.. .
Warner-lambert Company Llc

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Uses of oxygenated cholesterol sulfates (ocs)

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (mods), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (ocs), e.g.
Durect Corporation

Anti-cholesterolemic compounds and methods of use

The present invention provides novel compounds with hypocholesteremic activity from crude embilica officinialis (eo) extracts and methods of use. The invention also provides nutraceuticals..

Nasal vaccine for streptococcus pneumoniae

The present invention provides a nasal vaccine for streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of pspa, i.e.
Lsip, Llc

Nutritional composition

A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.. .
Hero Ag

Infusion of insulin into a patient and diabetes mellitus medical methods based on the patients monitored analyte concentration

Medical data provided by a physiological parameter sensor is used for management of the patient's medical condition. Analytes that may be monitored and managed include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., ck-mb), creatine, glucose, glutamine, growth hormones, hormones, ketones, lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, thyroid stimulating hormone, and troponin..
Abbott Diabetes Care Inc.

Method and system for extracting and using moomiyo compositions

A method and system for extraction of moomiyo from a multi-component, naturally-occurring mineral substance generally found in asian mountain ranges at elevations approximately between 1000 and 5000 meters. Bio-active compounds are extracted from said mineral substance for the medicinal applications including at least one of joint pain relief, skin care, anti-inflammation, bruise removal, decrease high blood cholesterol and high triglycerides levels, promotion of mental and physical energy, regulation of blood sugar levels, stimulation of the immune system, speeding of the recovery from sickness and wound healing therapies..

Diether based biodegradable cationic lipids for sirna delivery

Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Pegylated 7-dehydrocholesterol derivatives

The present invention relates to pegylated 7-dehydrocholesterol derivatives, and a composition for wrinkle alleviation and anti-aging comprising the same. The pegylated 7-dehydrocholesterol derivatives according to the present invention have improved stability and solubility in water, and thus can be effectively used as a good source for supplying vitamin d in a cosmetic composition, a pharmaceutical composition and a functional food for wrinkle alleviation and anti-aging..
Humedix Co., Ltd.

5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, hyper-ldl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group, and r1 is a hydrogen atom or a hydroxy group.. .
Daiichi Sankyo Company, Limited

Methods of using interleukin-10 for treating diseases and disorders

Methods for determining dosing parameters associated with subcutaneous administration of il-10 useful for the treatment and/or prevention of a cholesterol-related disease, disorder or condition, and pharmaceutical compositions associated therewith, are provided herein. Certain embodiments are directed to means for establishing a therapeutic range of an il-10 agent in a subject.
Armo Biosciences, Inc.

Proliposomal testosterone formulations

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc

Compositions based on methyl cyclodextrins for the treatment and/or prevention of diseases by increasing the hdl cholesterol level

The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (ms) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the hdl cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system.
Roquette Freres

Compounds, compositions and methods useful for cholesterol mobilization

The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein..
Cerenis Therapeutics Holding Sa

Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis

The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting acyl-coa: cholesterol acyltransferase 1 (acati) activity or expression in myeloid cells.. .
Trustees Of Dartmouth College

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

3,3′-disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.

Beta-lactam cholesterol absorption inhibitors

The present invention relates to the novel compounds represented by formula (ia) or (ib) and to their pharmaceutical preparations for the treatment of atherosclerosis and cholesterol level reduction.. .
Rudjer Boskovic Institute





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.123

file did exist - file did put2660

3 - 1 - 54